These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 17536871)

  • 21. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients.
    Govoni M; Poli G; Acerbi D; Santoro D; Cicirello H; Annoni O; Ružička J
    Pulm Pharmacol Ther; 2013 Apr; 26(2):249-55. PubMed ID: 23232039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
    Moss RB
    Chest; 2002 Jan; 121(1):55-63. PubMed ID: 11796432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
    Hodson ME; Gallagher CG; Govan JR
    Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
    Konstan MW; Geller DE; Minić P; Brockhaus F; Zhang J; Angyalosi G
    Pediatr Pulmonol; 2011 Mar; 46(3):230-8. PubMed ID: 20963831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
    Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
    J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
    Geller DE; Pitlick WH; Nardella PA; Tracewell WG; Ramsey BW
    Chest; 2002 Jul; 122(1):219-26. PubMed ID: 12114362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.
    Konstan MW; Flume PA; Galeva I; Wan R; Debonnett LM; Maykut RJ; Angyalosi G
    Pediatr Pulmonol; 2016 Apr; 51(4):372-8. PubMed ID: 26709158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
    Ramsey BW; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Kravitz RM; Schidlow DV; Wilmott RW; Astley SJ; McBurnie MA
    N Engl J Med; 1993 Jun; 328(24):1740-6. PubMed ID: 8497284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.
    Galeva I; Konstan MW; Higgins M; Angyalosi G; Brockhaus F; Piggott S; Thomas K; Chuchalin AG
    Curr Med Res Opin; 2013 Aug; 29(8):947-56. PubMed ID: 23672633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.
    Hamed K; Debonnett L
    Ther Adv Respir Dis; 2017 May; 11(5):193-209. PubMed ID: 28470103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.
    van Velzen AJ; Uges JWF; Heijerman HGM; Arets BGM; Nuijsink M; van der Wiel-Kooij EC; van Maarseveen EM; van Zanten GA; Pullens B; Touw DJ; Janssens HM
    Br J Clin Pharmacol; 2019 Sep; 85(9):1984-1993. PubMed ID: 31112621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microbiological and immunologic considerations with aerosolized drug delivery.
    LiPuma JJ
    Chest; 2001 Sep; 120(3 Suppl):118S-123S. PubMed ID: 11555566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
    [No Abstract]   [Full Text] [Related]  

  • 38. Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study.
    Mainz JG; Schädlich K; Schien C; Michl R; Schelhorn-Neise P; Koitschev A; Koitschev C; Keller PM; Riethmüller J; Wiedemann B; Beck JF
    Drug Des Devel Ther; 2014; 8():209-17. PubMed ID: 24596456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
    Wang X; Koehne-Voss S; Anumolu SS; Yu J
    J Pharm Sci; 2017 Nov; 106(11):3402-3409. PubMed ID: 28634121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
    Ratjen F; Munck A; Kho P; Angyalosi G;
    Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.